TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02334865

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incomplete Freund's Adjuvant
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Incomplete Freund's Adjuvant
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SVN53-67/M57-KLH Peptide Vaccine
Description: Given SC
Study: NCT03992794

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of MR-proADM
Description: It is an observational study. The only intervention was the measure of MR-proADM, but no clinical decision was made based on its value, since the physician attending the patient did´n know the value of MR-proADM
Study: NCT01674413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab PRN
Description: 160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with~* PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,~* Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is \< 167 mcg/gram of stool.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
Study: NCT02880748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water exchange (WE) method
Description: Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation (AI) method.
Description: Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
Study: NCT00855803

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Given in 1 or 5 fractions
Study: NCT01487070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen (Pegaptanib Sodium)
Description: Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.~Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only.
Study: NCT00908921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE
Description: Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
Study: NCT02218112

Intervention type: PROCEDURE
Intervention: bariatric surgery (gastric bypass)
Study: NCT02344420

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self assessment score
Description: patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
Study: NCT04282057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Radiofrequency protocol - The radiofrequency protocol was performed in dorsal decubitus, with the head elevated at 45 degrees. The application was in capacitive mode, with a 7cm electrode, always in movement. The duration of the application was established in 15 minutes, maintaining the local temperature between 40 to 42 celsius degrees at the epidermis.
Study: NCT03767881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AXIOS(TM) Stent and Electrocautery Enhanced Delivery System
Description: Patients who are at high risk or unsuitable for surgery will receive an AXIOS stent under EUS guidance for treatment of acute cholecystitis.
Study: NCT02341066

Intervention type: DEVICE
Intervention: Endothelial Dysfunction evaluation by EndoPAT
Description: Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
Study: NCT02827721

Intervention type: DEVICE
Intervention: impulse oscillometry

Intervention type: DEVICE
Intervention: impulse oscillometry
Study: NCT02993393

Intervention type: OTHER
Intervention: Teacher
Description: The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.

Intervention type: OTHER
Intervention: Student
Description: The students' questionnaire comprised 3 parts: learning content, process and evaluation.
Study: NCT01655914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil
Study: NCT04282057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Aerobic exercise protocol - 40 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen's formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (5 minutes); body (30 minutes); and cooling (from 5 to 10 minutes). The entire protocol was monitored through the Polar® brand heart rate monitor and watch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock wave therapy
Description: The shock wave device corresponds to the BTL-6000 X-Wave TM with a 20mm transmitter multifocal. The parameters used correspond to the pressure set between 2.8 and 3.5 bar, frequency 15 hertz and 3000 pulses per 10x15 cm area. It was used as a means contact gel for ultrasound, reference 033-051. In this procedure the participants found themselves in the supine position, with a pillow under the head and with the bending knees.
Study: NCT01231360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training
Description: Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal routine
Description: Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
Study: NCT03386578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Description: 200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Description: 200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)
Description: 200 mg/300 mg of FTC/TDF administered orally as a fixed-dose combination tablet once daily

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral HIV risk reduction package
Description: HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral HIV risk reduction package
Description: HIV risk reduction package, including cohort-appropriate SMS messages. Participants in the PrEP Comparison Component: Cohort 1 will also receive enhanced adherence support, including two-way SMS messaging and tailored counseling with near-real time drug level feedback.
Study: NCT01684475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJH1 (CLR4001)
Study: NCT01036490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training for 12 weeks followed by home exercise for 40 weeks
Study: NCT03838445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Wave Interatrial Shunt
Description: The V-Wave Interatrial Shunt System, includes a permanent implant placed during a minimally invasive cardiac catheterization procedure using its dedicated Delivery Catheter. The device is implanted through the fossa ovals and straddles the interatrial septum.
Study: NCT01452555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video or In-Person Presentation
Description: Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video or In-Person Presentation
Description: Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
Study: NCT03146221

Intervention type: OTHER
Group type: OTHER
Intervention: To look for serum microRNA profiles associated with restenosis
Description: To look for serum microRNA profiles associated with restenosis
Study: NCT01413542

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin (DPP4 inhibitor)
Description: Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin (DPP4 inhibitor)
Description: Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin (DPP4 inhibitor)
Description: Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin (DPP4 inhibitor)
Description: Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Substance P,
Description: Substance P intra-brachial artery (2,4,8 pmol/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Substance P,
Description: Substance P intra-brachial artery (2,4,8 pmol/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bradykinin
Description: bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
Study: NCT03386539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus capsule or liquid suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus capsule or liquid suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil capsule or liquid suspension
Study: NCT01919450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
Study: NCT04335175

Intervention type: OTHER
Intervention: None - observational study
Description: None - observational study

Intervention type: OTHER
Intervention: None - observational study
Description: None - observational study

Intervention type: OTHER
Intervention: None - observational study
Description: None - observational study
Study: NCT03245645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Intervention
Description: Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
Study: NCT00173537

Intervention type: PROCEDURE
Group type: OTHER
Intervention: for BMPR II study

Intervention type: GENETIC
Group type: OTHER
Intervention: BMPRII
Study: NCT02148861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Administered once-weekly subcutaneously (s.c., under the skin) for 35 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once-daily subcutaneously (s.c., under the skin) for 35 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once-daily for 35 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once-daily for 35 days
Study: NCT03504280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study: NCT04341649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Head Massage
Description: Duration 10 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BREO Helmet Massager
Description: Duration 10 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Laser Therapy (LLT)
Description: Duration 7 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham LLT
Description: Duration 7 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS ear stimulation
Description: Duration 7 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deep and Slow breathing
Description: A full respiratory cycle of 10 seconds with 5 seconds for inspiration and 5 seconds for expiration.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Relaxed Reading time
Description: Duration 10 minutes.
Study: NCT00922987

Intervention type: DRUG
Intervention: Lyrica (pregabalin)
Description: The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
Study: NCT03983694

Intervention type: OTHER
Intervention: Erythrocyte transfusion
Description: The cerebro-vascular effects of a clinically prescribed erytrocyte (red blood cell) transfusion is examined. Before the transfusion, BabyLux sensor is placed on the neonatal fronto-parietal region and held in place by a self-adhesive bandage. A baseline prior to transfusion is established through a series of five repeated measurements of 1 minute taken during a stable period just before the transfusion is started. Once transfusion has ended, another series of five repeated measurements of 1 minute taken during a stable period are performed to determine the responses. Cerebral oxygenation as determined by a commercial spatially resolved NIRS device with neonatal sensor will be continuously recorded during transfusion.
Study: NCT02397005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZL-2102
Description: A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ZL-2102
Study: NCT04238832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Salt Base Nicotine
Description: Participants will try both free base and salt base nicotine e-liquid and then take home salt base nicotine

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Base Nicotine
Description: Participants will try both free base and salt base nicotine e-liquid and then take home free base nicotine
Study: NCT01762826

Intervention type: DIETARY_SUPPLEMENT
Intervention: Myo-inositol
Description: Dietary control plus Myo-inositol

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-chiro-inositol
Description: Dietary control plus D-Chiro-Inositol supplementation

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-Chiro / Myo-inositol
Description: Dietary control Supplementation with myo and d-chiro inositol

Intervention type: DIETARY_SUPPLEMENT
Intervention: Placebo
Description: Dietary control plus folic acid 400 mcg daily
Study: NCT00345059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT01741779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration Training
Description: The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Description: The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration training & diet
Description: Combination of whole body vibration training and hypocaloric diet
Study: NCT00569790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Irinotecan, Bevacizumab
Description: S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA \<1.25m2), 50 mg (BSA \>1.25 to \<1.50 m2), or 60 mg (BSA \>1.50 m2).~Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15.
Study: NCT02865395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belladonna and Opium Suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belladonna and Opium Suppository

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rectal Exam